医疗ETF（159828）涨超2.7%，创新与国际化驱动估值重估

Group 1 - The core viewpoint is that brain-computer interfaces (BCIs) are at the critical point of industrialization, with significant support from major countries like China and the U.S. [1] - The "14th Five-Year Plan" in China identifies BCIs as one of the six future industries, with goals set for technological breakthroughs by 2027 and the formation of an industrial ecosystem by 2030 [1] - The global brain market is projected to reach $7.63 billion by 2029, indicating a rapidly emerging market opportunity [1] Group 2 - The medical field is currently the most mature and largest commercial application area for BCIs, with clinical trials in China covering diseases such as stroke rehabilitation and quadriplegia [1] - Policy support, including medical insurance pricing, is expected to facilitate the deployment of related devices in the healthcare sector [1] - China is making significant progress in invasive and semi-invasive BCI technologies, with notable advancements in flexible electrode technology and Chinese language decoding [1] Group 3 - Investment in the pharmaceutical sector should focus on the intrinsic logic of clinical value, particularly in innovative medical devices, high-end equipment, and high-value consumables [1] - The medical ETF (159828) tracks the CSI Medical Index (399989), which includes listed companies in medical devices, services, and information technology, reflecting the overall performance of China's medical theme stocks [1] - The index consists of approximately 50 constituent stocks, concentrated in the healthcare sector, characterized by high growth potential and volatility [1]